Treatment strategies for protein-losing enteropathy in Fontan-palliated patients
Objective:
Protein-losing enteropathy is an infrequent but severe condition occurring after Fontan procedure. The multifactorial pathogenesis remains unclear and no single proposed treatment strategy has proven universally successful. Therefore, we sought to describe different treatment strategies and their effect on clinical outcome and mortality.
Material and Methods:
We performed a retrospective observational study. From the total cohort of 439 Fontan patients treated in our institution during the study period 1986–2019, 30 patients (6.8%) with protein-losing enteropathy were identified. Perioperative, clinical, echocardiographic, laboratory, and invasive haemodynamic findings and treatment details were analysed.
Results:
Median follow-up after disease onset was 13.1 years [interquartile range 10.6]. Twenty-five patients received surgical or interventional treatment for haemodynamic restrictions. Medical treatment, predominantly pulmonary vasodilator and/or systemic anti-inflammatory therapy with budesonide, was initiated in 28 patients. In 15 patients, a stable remission could be achieved by medical or surgical procedures (n = 3 each), by combined multimodal therapy (n = 8), or ultimately by cardiac transplantation (n = 1). Phrenic palsy, bradyarrhythmia, Fontan pathway stenosis, and absence of a fenestration were significantly associated with development of protein-losing enteropathy (p = 0.001–0.48). Ten patients (33.3%) died during follow-up; 5-year survival estimate was 96.1%. In unadjusted analysis, medical therapy with budesonide and pulmonary vasodilator therapy in combination was associated with improved survival.
Conclusions:
Protein-losing enteropathy is a serious condition limiting survival after the Fontan procedure. Comprehensive assessment and individual treatment strategies are mandatory to achieve best possible outcome. Nevertheless, relapse is frequent and long-term mortality substantial. Cardiac transplantation should be considered early as treatment option.
Top-30
Journals
|
1
2
3
|
|
|
International Journal of Cardiology Congenital Heart Disease
3 publications, 13.04%
|
|
|
Journal of Heart and Lung Transplantation
2 publications, 8.7%
|
|
|
European Journal of Cardio-thoracic Surgery
2 publications, 8.7%
|
|
|
Korean Circulation Journal
2 publications, 8.7%
|
|
|
Cardiology in the Young
2 publications, 8.7%
|
|
|
Life
1 publication, 4.35%
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 4.35%
|
|
|
Frontiers in Pediatrics
1 publication, 4.35%
|
|
|
Canadian Journal of Cardiology
1 publication, 4.35%
|
|
|
International Journal of Cardiology
1 publication, 4.35%
|
|
|
Acta Paediatrica, International Journal of Paediatrics
1 publication, 4.35%
|
|
|
Thoracic and Cardiovascular Surgeon
1 publication, 4.35%
|
|
|
World journal for pediatric & congenital heart surgery
1 publication, 4.35%
|
|
|
Journal of Hepatology
1 publication, 4.35%
|
|
|
Therapie der Krankheiten im Kindes- und Jugendalter
1 publication, 4.35%
|
|
|
Diagnostics
1 publication, 4.35%
|
|
|
Pediatric Cardiology
1 publication, 4.35%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
Elsevier
8 publications, 34.78%
|
|
|
MDPI
2 publications, 8.7%
|
|
|
Frontiers Media S.A.
2 publications, 8.7%
|
|
|
Oxford University Press
2 publications, 8.7%
|
|
|
Cambridge University Press
2 publications, 8.7%
|
|
|
Springer Nature
2 publications, 8.7%
|
|
|
Wiley
1 publication, 4.35%
|
|
|
Georg Thieme Verlag KG
1 publication, 4.35%
|
|
|
The Korean Society of Cardiology
1 publication, 4.35%
|
|
|
SAGE
1 publication, 4.35%
|
|
|
Korean Society of Circulation
1 publication, 4.35%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.